KRAS and lung adenocarcinoma: Based on TCGA data, pathways activated by EGFR mutations were found in 11% of tumors, K-RAS mutations in 32%, PI3K mutations in 4%, HER2 in 3% and PTEN inactivation in 3% of lung adenocarcinoma samples [6].